The European interventional oncology device market will be driven by moderate procedure volume growth, spurred by enhanced cancer detection, rising patient and physician awareness, improved reimbursement, and increased physician training on interventional oncology procedures. This market will continue to be characterized by rapid cannibalization of RF ablation by microwave ablation, new emerging technologies, and strong competition between embolization particle treatments.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Europe across a 10-year period.


Reimbursement will be an important factor in the adoption of interventional oncology procedures.

How do reimbursement policies vary among the different European countries covered?

How will different reimbursement policies impact the uptake of interventional oncology? 

Ablation therapy procedures will continue to grow for liver, kidney, and lung cancer while novel indications such as prostate and pancreatic cancer represent new opportunities for growth.

What are the advantages and disadvantages of each type of ablation device offered by competitors and how do these differences affect adoption for different indications?

What are the major demographic, economic, and local trend differences across Europe that impact the adoption of these devices?

Microwave ablation is cannibalizing RF ablation owing to the former's increased popularity among physicians, while newer technologies such as cryoablation and IRE are also being adopted.

What are the advantages and disadvantages of each type of ablation device?

How does the uptake of microwave ablation devices affect other types of ablation devices, like RF ablation devices, and how are competitors preparing for this shift?

In which indications will these newer ablation devices experience the fastest adoption?

Radioembolization spheres continue to represent the largest segment of the embolization particle market, although the microsphere and DEB markets will also experience growth over the forecast period.

How will outcomes of trials like SIRFLOX and FOXFIRE affect the adoption and usage of radioembolization spheres?

What factors are contributing to the growth of  the European microsphere and DEB markets?

Product improvements and innovations will drive growth in the European interventional oncology market.

What new products are anticipated to be launched in Europe? What product features are companies focusing on during novel product development?

Are there any ongoing clinical studies investigating innovative products and improved product features?

Table of contents

  • Europe
    • Abstract
    • Executive Summary
      • Market Highlights
      • Competitive Highlights
      • Market Developments
      • End-User Insights
      • Key Report Updates
      • Geographies Covered
      • Procedures Covered
      • Products Covered
    • Version History
    • Interventional Oncology Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Product Portfolio Management
        • Clinical Data
        • Reimbursement
        • Mergers, Acquisitions, and Partnerships
        • Product Improvements and Innovations
        • Physician Training and Marketing
        • Distribution and Sales Network
      • Market Developments
    • Ablation Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • Radiofrequency Ablation Devices
        • Microwave Ablation Devices
        • Cryoablation Devices
        • Irreversible Electroporation Ablation
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
    • Embolization Particle Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • Radioembolization Spheres
        • Drug-Eluting Beads
        • Microspheres
        • PVA Particles
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Clinical Data
    • Appendix
      • Abbreviations
      • Bibliography

Author(s): Bishwjit Ghoshal, MBA

Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.


Related Reports

Interventional Oncology Devices | Medtech 360 | Market Insights | Asia Pacific

Despite pricing pressures and the release of mixed clinical data, the Asia Pacific interventional oncology device market will expand rapidly through 2027, driven by the continued growth of cance...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Asia Pacific (Supplemental)

The Asia Pacific market for interventional oncology will expand through 2027, driven primarily by continued growth of cancer incidence, improving access to treat...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Europe (Supplemental)

The European interventional oncology device market will be characterized by procedure volume growth, spurred by enhanced reimbursement, product improvements, and the availability of new technolo...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | United States

The US market for interventional oncology devices continues to grow, driven by expanding treatable patient populations and increasing uptake of premium-priced technology. However, growth in...

View Details